Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual General Meeting.
Riad Mishlawi, Hikma’s CEO, said:
“Hikma has had a strong start to 2024, with continued growth and momentum across the Group. Our three businesses are performing well, underpinned by our strong commercial and operational capabilities. We are launching new products and expanding our manufacturing capacity, which will drive sustainable future growth.”
Group
The Group had a strong and encouraging start to the year, supported by all three business segments.
We expect Group revenue to grow in the range of 4% to 6% and for core operating profit to be in the range of $660 million to $700 million in 2024, in line with prior guidance.
Injectables
Our global Injectables business has had a good start to the year. In the US, the breadth of our portfolio, new launches, and our new high speed filling lines are enabling us to capture new market opportunities. In Europe, we are benefitting from good demand for our own products and we continue to make progress in new markets. We are also seeing solid growth across our MENA markets, supported by our biosimilar portfolio and recent launches.
We have launched three products year-to-date in the US and are expanding our global manufacturing capacity, including strengthening our sterile manufacturing capabilities in MENA.
We continue to expect 2024 Injectables revenue to grow in the range of 6% and 8% and for core operating margin to be between 36% and 37%.
Branded
Building on recent momentum, Branded has had a strong start to the year, supported by a growing product portfolio and our commercial and operational strength in the MENA region. We are seeing strong demand across our MENA markets and increased sales both for our portfolio of oncology medicines and for those medicines used to treat chronic illnesses.
In 2023 we became the second largest pharmaceutical company in MENA by sales[1]. We are investing in R&D to launch more complex and first-to-market products. We are also gaining market share in key therapeutic areas – we are the sixth largest supplier of new generation type II diabetes products and second largest for multiple sclerosis therapies[2]. We are investing in enhancing our manufacturing capacity and capabilities, strengthening our position as a local manufacturer and supplier of high-quality medicines with industry-leading global expertise.
For 2024, we continue to expect Branded revenue to grow in the mid- to high-single digits in constant currency, or low-single digits on a reported basis. Given the strong performance in the year to date, we now expect slight growth in reported core operating profit.
Generics
Our Generics business is performing well. This reflects a robust performance from our broad product portfolio and recent launches. We are focusing on building a differentiated portfolio and pipeline for this business, as well as leveraging our state-of-the-art facility in Columbus, Ohio.
Last week, Hafrun Fridriksdottir was appointed as President of the Generics business. Hafrun brings more than 25 years of strong leadership and deep pharmaceutical industry experience to her new role, with a particular emphasis on research and development, successful pipeline expansion and new product introductions, making her well positioned to lead Hikma’s Generics business in its next phase of growth.
We continue to expect Generics revenue to grow in the range of 3% to 5% in 2024. We expect 2024 core operating margin to be in the mid-teens, reflecting the increase in royalties payable on our authorised generic of sodium oxybate.
Final dividend
Subject to approval at today’s Annual General Meeting, we will be paying a final dividend of 47 cents per share. The final dividend brings the total dividend for the full year 2023 to 72 cents per share, an increase of 29% on 2022. This equates to a payout ratio of around 32%, which is above our historical range of 20% to 30%. We intend to progressively increase our dividend, with a payout ratio in the range of 30% to 40%, reflecting the Board’s confidence in the long-term growth prospects for the Group and our ongoing commitment to return cash to shareholders.
We will announce our interim results for the six months ended 30 June 2024 on 8 August 2024.
Forward-looking statements
Hikma advises shareholders to approach forward-looking statements with caution due to potential risks and uncertainties, as outlined in the company's Annual Report. While these statements are made in good faith based on available information, actual results may differ. Hikma does not guarantee updates to forward-looking statements beyond legal or regulatory obligations, and shareholders are warned against placing undue reliance on them. Other than in accordance with its legal or regulatory obligations (including under the UK Market Abuse Regulation and the UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), Hikma does not undertake to update any forward-looking statements contained in this announcement to reflect any changes in events, conditions or circumstances on which any such statement is based or to correct any inaccuracies which may become apparent in any such forward-looking statements.
[1] IQVIA MIDAS Pharma Index MAT Feb-2024. Retail + Hospital. Excluding Milks and diagnostics. Excluding Lebanon.
[2] IQVIA MIDAS Pharma Index MAT Feb-2024. Retail + Hospital. Excluding Milks and diagnostics. Excluding Lebanon. Excluding F & G NFC1
Permalink
https://aetoswire.com/en/news/2504202438912
Contacts
Susan Ringdal
EVP, Strategic Planning and Global Affairs
+44(0)2073992760 / +44(0)7776477050
Guy Featherstone
Director, Investor Relations
+44 (0)2038924389 / +44(0)7795896738
Layan Kalisse
Senior Associate, Investor Relations
+44(0)2073992788 / +44(0)7970709912
No comments:
Post a Comment